11-108310218-G-C

Variant summary

Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM1

The NM_000051.4(ATM):ā€‹c.5821G>Cā€‹(p.Val1941Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000254 in 1,613,470 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V1941G) has been classified as Uncertain significance.

Frequency

Genomes: š‘“ 0.00017 ( 0 hom., cov: 32)
Exomes š‘“: 0.00026 ( 0 hom. )

Consequence

ATM
NM_000051.4 missense

Scores

3
11
5

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:16B:5

Conservation

PhyloP100: 7.27
Variant links:
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]
C11orf65 (HGNC:28519): (chromosome 11 open reading frame 65) Predicted to be involved in negative regulation of mitochondrial fission and negative regulation of protein targeting to mitochondrion. Predicted to be located in cytosol and mitochondrial outer membrane. [provided by Alliance of Genome Resources, Apr 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 2 ACMG points.

PM1
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 16 uncertain in NM_000051.4

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
ATMNM_000051.4 linkuse as main transcriptc.5821G>C p.Val1941Leu missense_variant 39/63 ENST00000675843.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
ATMENST00000675843.1 linkuse as main transcriptc.5821G>C p.Val1941Leu missense_variant 39/63 NM_000051.4 P1

Frequencies

GnomAD3 genomes
AF:
0.000171
AC:
26
AN:
152112
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000655
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000368
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000131
AC:
33
AN:
251056
Hom.:
0
AF XY:
0.000133
AC XY:
18
AN XY:
135724
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000290
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000255
Gnomad OTH exome
AF:
0.000490
GnomAD4 exome
AF:
0.000263
AC:
384
AN:
1461358
Hom.:
0
Cov.:
31
AF XY:
0.000245
AC XY:
178
AN XY:
727002
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000321
Gnomad4 OTH exome
AF:
0.000398
GnomAD4 genome
AF:
0.000171
AC:
26
AN:
152112
Hom.:
0
Cov.:
32
AF XY:
0.0000942
AC XY:
7
AN XY:
74302
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.0000655
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000368
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000263
Hom.:
0
Bravo
AF:
0.000117
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.0000824
AC:
10
EpiCase
AF:
0.000491
EpiControl
AF:
0.000356

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:16Benign:5
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:6
Uncertain significance, criteria provided, single submitterclinical testingGeneDxOct 21, 2024In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 16014569, 19781682, 21787400, 16832357, 21933854, 25503501, 25980754, 26580448, 25925381, 28971906, 29909963, 29522266, 25186627, 28779002, 28652578, 31843900, 9764584, 33471991, 33436325, 19431188, 35980532, 35534704, 34326862, 34262154) -
Uncertain significance, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenJul 01, 2024ATM: PS3:Supporting -
Uncertain significance, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesMay 05, 2020- -
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoAug 11, 2021- -
Uncertain significance, criteria provided, single submitterclinical testingAthena DiagnosticsMar 21, 2018- -
Uncertain significance, criteria provided, single submitterclinical testingCenter for Pediatric Genomic Medicine, Children's Mercy Hospital and ClinicsJan 18, 2016- -
Hereditary cancer-predisposing syndrome Pathogenic:1Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsFeb 01, 2024The p.V1941L variant (also known as c.5821G>C), located in coding exon 38 of the ATM gene, results from a G to C substitution at nucleotide position 5821. The valine at codon 1941 is replaced by leucine, an amino acid with highly similar properties. One functional analysis of this variant showed an associated reduction, but not absence, of ATM kinase activity (Barone G et al. Hum. Mutat. 2009 Aug;30:1222-30). Across numerous studies, this alteration has been observed in multiple cancer cohorts and control groups (Tavtigian SV et al. Am. J. Hum. Genet. 2009 Oct;85:427-46; Skowronska A et al. Haematologica. 2012 Jan;97:142-6; Tung N et al. Cancer. 2015 Jan;121:25-33; Zhang J et al. N Engl J Med, 2015 Dec;373:2336-2346; Decker B et al. J Med Genet. 2017 11;54:732-741; Hauke J et al. Cancer Med. 2018 04;7:1349-1358; Karlsson Q et al. Eur Urol Oncol, 2021 Aug;4:570-579). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. -
Likely benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthAug 19, 2021- -
Likely pathogenic, flagged submissionresearchAcademic Department of Medical Genetics, University of CambridgeJan 26, 2018Application of AMCG guidelines 2015. Used other ClinVar submission evidence where relevant. Loss of heterozygosity in tumours or immunohistochemistry abnormalities considered functional evidence of pathogenicity. -
Uncertain significance, criteria provided, single submittercurationSema4, Sema4Dec 07, 2021- -
Ataxia-telangiectasia syndrome Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaAug 16, 2017This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
Likely benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
Uncertain significance, criteria provided, single submitterclinical testingCounsylNov 10, 2017- -
Uncertain significance, criteria provided, single submitterclinical testingMendelicsJul 02, 2018- -
Familial cancer of breast Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitterclinical testingSt. Jude Molecular Pathology, St. Jude Children's Research HospitalMay 23, 2023The ATM c.5821G>C (p.Val1941Leu) missense change has a maximum subpopulation frequency of 0.025% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL is inconclusive about a pathogenic or benign effect of this variant on protein function. A functional study has shown reduced ATM protein level and kinase activity (PMID: 19431188). This variant has been identified in individuals with breast cancer (PMID: 16832357, 25186627, 28779002, 29522266, 35980532), an individual undergoing clinical genetic testing for Lynch syndrome (PMID: 25980754), and an individual with multiple primary tumors or with a single primary tumor and a first-degree relative with multiple primary tumors (PMID: 29909963). In addition, in case-control studies the variant was present at similar or low frequencies in breast cancer patients compared to control subjects (PMID: 19781682, 28779002). This variant is present 10x in a database of women older than 70 years of age who have never had cancer (FLOSSIES database, https://whi.color.com/). To our knowledge, this variant has not been reported in individuals with ataxia telangiectasia. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -
Likely benign, criteria provided, single submitterclinical testingMyriad Genetics, Inc.May 24, 2024This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsMar 29, 2024- -
not specified Benign:2
Benign, no assertion criteria providedresearchKing Laboratory, University of WashingtonSep 01, 2019- -
Likely benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpJul 31, 2024Variant summary: ATM c.5821G>C (p.Val1941Leu) results in a conservative amino acid change located in the PIK-related kinase domain of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00013 in 251056 control chromosomes, predominantly at a frequency of 0.00026 within the Non-Finnish European subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in ATM causing breast/ATM-related cancer and/or Ataxia Telangiectasia. However, the variant was also reported in 10 / 9884 women (i.e. with a frequency of about 0.001), who were older than 70 years of age, and never had cancer (FLOSSIES database), which might suggest a benign outcome for the variant. c.5821G>C has been reported in the literature in individuals affected with breast cancer (e.g. Shayeghi_1998, Renwick_2006, Maxwell_2015, Pereira_2022), other tumor phenotypes such as chronic lymphocytic leukemia (CLL), Lynch syndrome-associated cancer and/or polyps, pediatric low grade glioma (e.g. Skowronska_2011, Yurgelun_2015, Zhang_2015, Tung_2015) and also in several healthy controls (e.g. Tavtigian_2009, Skowronska_2011, Tiao_2017, Yu_2022). Recent case-control studies showed that the frequencies of this variant are similar in cases (breast cancer, prostate cancer, or pancreatic cancer) and controls, indicating this variant does not associate with breast, prostate, or pancreatic cancer (Dorling_2021, Karlsson_2021, Yu_2022). Furthermore, a co-occurrence with another pathogenic variant (BRCA1 c.3607C>T, p.Arg1203X) has been observed for this variant (internal sample). Using an ATM-null lymphoblastoid cell line (LCL) transfected with the variant of interest, Barone et al demonstrated an approximately 50% decrease in protein expression (or stability), yet no significant decrease in specific kinase activity (Barone_2009). The following publications have been ascertained in the context of this evaluation (PMID: 19431188, 33471991, 33436325, 25503501, 35980532, 16832357, 9764584, 21933854, 19781682, 28652578, 25186627, 29909963, 35047863, 25980754, 26580448). ClinVar contains an entry for this variant (Variation ID: 127412). Based on the evidence outlined above, the variant was classified as likely benign. -
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingCHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern OntarioOct 20, 2022- -
Ataxia-telangiectasia syndrome;C0346153:Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsMay 23, 2017- -
ATM-related disorder Uncertain:1
Uncertain significance, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesAug 13, 2024The ATM c.5821G>C variant is predicted to result in the amino acid substitution p.Val1941Leu. This variant has been identified in individuals with breast cancer (Table S2, Renwick et al. 2006. PubMed ID: 16832357; Table S1, Maxwell et al. 2015. PubMed ID: 25503501, Table S4, Bhai et al. 2021. PubMed ID: 34326862), chronic lymphocytic leukemia (Table S2, Skowronska et al. 2012. PubMed ID: 21933854), and suspected Lynch syndrome (Table S2, Yurgelun et al. 2015. PubMed ID: 25980754). Functional analysis showed that this variant results in reduced ATM protein activity (Barone et al. 2009. PubMed ID: 19431188). However, in case-control studies, this variant was identified with similar frequencies between controls and individuals with breast cancer or chronic lymphocytic leukemia (Table S2, Tavtigian et al. 2009. PubMed ID: 19781682; Table S2, Skowronska et al. 2012. PubMed ID: 21933854). This variant is reported in 0.025%of alleles in individuals of European (Non-Finnish) descent in gnomAD and has conflicting interpretations of pathogenicity in ClinVar ranging from benign to uncertain (http://www.ncbi.nlm.nih.gov/clinvar/variation/127412). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.53
BayesDel_addAF
Pathogenic
0.16
D
BayesDel_noAF
Pathogenic
0.29
CADD
Uncertain
25
DANN
Uncertain
0.99
DEOGEN2
Benign
0.12
T;T
Eigen
Uncertain
0.61
Eigen_PC
Uncertain
0.64
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Uncertain
0.87
D;.
M_CAP
Uncertain
0.16
D
MetaRNN
Uncertain
0.59
D;D
MetaSVM
Uncertain
-0.12
T
MutationAssessor
Uncertain
2.6
M;M
MutationTaster
Benign
1.0
D;D;D
PrimateAI
Uncertain
0.62
T
PROVEAN
Benign
-1.5
N;N
REVEL
Uncertain
0.55
Sift
Benign
0.093
T;T
Sift4G
Benign
0.14
T;T
Polyphen
0.82
P;P
Vest4
0.73
MVP
0.93
MPC
0.34
ClinPred
0.16
T
GERP RS
5.7
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.55
gMVP
0.65

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.060
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs147187700; hg19: chr11-108180945; COSMIC: COSV53750671; API